Report Description Table of Contents How Are Targeted Therapies, Clinical Innovation, and Expanding Treatment Access Transforming the Global Niemann-Pick Disease Type C Treatment Market? Increasing diagnosis of Niemann-Pick Disease Type C (NPC), growing demand for treatments that slow neurological deterioration, and the availability of newly approved medicines are creating opportunities for pharmaceutical manufacturers and specialized healthcare providers. Strategic Market Research estimates the Global Niemann-Pick Disease Type C Treatment Market at USD 191.87 million in 2025, with revenue projected to reach USD 745.00 million by 2032. The anticipated 21.38% CAGR during 2026–2032 reflects expanding access to targeted therapies such as MIPLYFFA and AQNEURSA, improved identification of undiagnosed patients, and increasing adoption of long-term treatment to manage neurological symptoms. According to Zevra Therapeutics' August 2026 SEC filing, approximately 2,000 people are estimated to be living with Niemann-Pick Disease Type C (NPC) in the U.S. and Europe, including 900 in the U.S. and 1,100 in Europe. However, only 300–350 U.S. patients are estimated to have been diagnosed, meaning many people may still be unaware they have the disease. This gap highlights the need for earlier diagnosis and better access to treatment. NPC treatment mainly focuses on slowing damage to the brain and nervous system. Patients can experience difficulties with walking, speaking, swallowing, and memory. In September 2024, the U.S. FDA approved MIPLYFFA (arimoclomol) for patients aged two years and older, alongside miglustat. The FDA also approved AQNEURSA (levacetylleucine) for adults and children weighing at least 15 kg, expanding treatment options for patients with neurological symptoms. The Niemann-Pick Disease Type C Treatment Market through 2032 will be shaped by the growing use of MIPLYFFA and AQNEURSA, the identification of undiagnosed NPC patients, and the availability of insurance coverage for specialized medicines. Which Treatment Categories, Patient Groups, and Distribution Channels Are Leading the Niemann-Pick Disease Type C Treatment Market? By Treatment Type: Arimoclomol Leads as Levacetylleucine Adoption Accelerates Leading Subsegment: Arimoclomol-Based Therapy Arimoclomol-based therapy leads the Niemann-Pick Disease Type C Treatment Market, accounting for an estimated 36% market share, equivalent to USD 69.07 million in 2025, and is projected to grow at a CAGR of 24.5% during 2026–2032. Market leadership is supported by the September 2024 FDA approval of Miplyffa (arimoclomol), the first FDA-approved oral treatment for Niemann-Pick disease type C, authorized for patients aged 2 years and older in combination with miglustat. Regulatory approval, improved treatment accessibility, and growing clinical adoption are strengthening arimoclomol's commercial position. Fastest-Growing Subsegment: Levacetylleucine Therapy Levacetylleucine therapy accounts for an estimated 25% share of the global Niemann-Pick Disease Type C Treatment Market, representing USD 47.97 million in 2025, and is projected to register the fastest CAGR of 26.5% during 2026–2032. Commercialized as AQNEURSA, levacetylleucine is an FDA-approved oral therapy targeting neurological manifestations of Niemann-Pick disease type C (NPC). Its growing clinical adoption is supported by improvements in neurological function, convenient oral administration, and increasing physician awareness, strengthening its position within the evolving therapeutic landscape for NPC management. By Drug Type: Approved Oral Medicines Expand Neurological Treatment Access Leading Subsegment: Arimoclomol Arimoclomol, marketed as Miplyffa, holds the largest estimated 43% share of the global Niemann-Pick Disease Type C Treatment Market, contributing USD 82.50 million in 2025, with a projected CAGR of 23.3% during 2026–2032. Its market leadership is supported by FDA approval as an oral small-molecule therapy administered alongside miglustat to treat neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older. Growing clinical adoption and broader treatment accessibility are expected to strengthen its commercial position. Fastest-Growing Subsegment: Levacetylleucine Levacetylleucine, marketed as Aqneursa, accounts for an estimated 32% share of the global Niemann-Pick Disease Type C Treatment Market, valued at USD 61.40 million in 2025, and is projected to register the fastest CAGR of 24.2% during 2026–2032. FDA-approved as an oral small-molecule therapy, Aqneursa treats neurological manifestations of Niemann-Pick disease type C in adults and pediatric patients weighing at least 15 kg (33 lbs). Its targeted neurological benefits, oral administration, and expanding treatment accessibility support its strong growth prospects. By Patient Age Group: Pediatric Patients Lead Treatment Adoption and Expansion Leading and Fastest-Growing Subsegment: Pediatric Patients Pediatric patients hold the largest share of the Niemann-Pick Disease Type C Treatment Market, accounting for approximately 76% and contributing USD 145.82 million in 2025, with the fastest projected CAGR of 22.5% during 2026–2032. The segment’s dominance reflects the early onset of NPC, characterized by progressive neurological deterioration, impaired motor coordination, cognitive decline, and visceral complications during childhood. Increasing emphasis on early diagnosis, disease-modifying therapies, and long-term neurological management continues to strengthen pediatric treatment adoption and improve clinical intervention opportunities. By Route of Administration Leading and Fastest-Growing Subsegment: Oral Administration Oral administration dominates the Niemann-Pick Disease Type C Treatment Market, accounting for an estimated 90% market share, equivalent to USD 172.68 million in 2025, and is projected to register the fastest CAGR of 21.8% during 2026–2032. Its leadership is supported by the growing clinical adoption of oral disease-modifying therapies, including arimoclomol and miglustat, which target neurological manifestations of NPC. Oral treatment offers convenient long-term administration, while therapeutic benefits include slowing neurological deterioration and helping preserve essential functions such as swallowing, mobility, and daily motor coordination, supporting sustained treatment adherence. By Distribution Channel: Specialty Pharmacies Lead Access to Long-Term Therapy Leading and Fastest-Growing Subsegment: Specialty Pharmacies Specialty pharmacies lead the Niemann-Pick Disease Type C Treatment Market distribution category, accounting for an estimated 67% market share, valued at USD 128.55 million in 2025, and are projected to register the fastest CAGR of 24.0% during 2026–2032. Their leadership reflects their critical role in connecting drug manufacturers, healthcare providers, and patients requiring specialized NPC therapies. Specialty pharmacies facilitate access to orphan drugs, coordinate insurance approvals, provide medication counseling, and support long-term treatment adherence for patients managing this ultra-rare, progressive neurodegenerative disorder. By Geography: North America Leads as Asia-Pacific Expands Specialty Care Leading Region: North America North America dominates the global Niemann-Pick Disease Type C Treatment Market, accounting for an estimated 52% market share, valued at USD 99.77 million in 2025, with a projected CAGR of 20.0% during 2026–2032. Regional leadership is supported by the growing adoption of disease-modifying therapies, particularly following FDA approvals of Miplyffa (arimoclomol) and Aqneursa (levacetylleucine) in 2024. The transition from conventional symptom management toward targeted NPC treatments, supported by specialized rare disease centers, improved diagnostic capabilities, and expanding therapeutic access, is strengthening North America's treatment landscape. Fastest-Growing Region: Asia-Pacific Asia-Pacific accounted for an estimated 10% share of the global Niemann-Pick Disease Type C Treatment Market, representing approximately USD 19.19 million in 2025, and is projected to record the fastest regional CAGR of 27.0% during 2026–2032. Treatment adoption across the region is influenced by regulatory approval complexities, dependence on imported specialty medications, and evolving clinical management practices. Expanding rare disease screening programs, improving diagnostic capabilities, and growing access to specialized neurological care are expected to support treatment uptake across China, Japan, India, and other regional healthcare markets. Which Pharmaceutical Companies Are Advancing Targeted Therapies and Clinical Innovation in the Niemann-Pick Disease Type C Treatment Market? Zevra Therapeutics Zevra Therapeutics is a leading commercial participant in the Niemann-Pick disease type C (NPC) treatment market, supported by its FDA-approved therapy Miplyffa (arimoclomol). Approved in September 2024 for use alongside miglustat in patients aged two years and older, Miplyffa represents an important advancement in neurological disease management. The treatment is an orally administered small-molecule therapy investigated for its effects on cellular stress-response pathways. Zevra reported USD 87.4 million in Miplyffa net product revenue during 2025, compared with USD 10.1 million in 2024, representing approximately an 765% increase. Miplyffa generated an additional USD 30.2 million in the second quarter of 2026. By December 2025, the company had received 161 cumulative prescription enrollment forms since launch and reported market access covering approximately 68% of insured lives within its reported coverage framework. These developments establish Zevra's commercial position through specialty pharmaceutical distribution, reimbursement access, and continued treatment adoption. Other Key Companies and Their Roles: IntraBio: Developed Aqneursa (levacetylleucine), an FDA-approved oral neurological therapy evaluated in a 60-patient clinical trial; Shionogi announced an agreement to acquire IntraBio in October 2026. Johnson & Johnson: Through Janssen, historically commercialized Zavesca (miglustat), a substrate reduction therapy that inhibits glucosylceramide synthase; the European marketing authorization is currently held by Advanz Pharma. Cyclo Therapeutics: Now part of Rafael Holdings, develops Trappsol Cyclo (hydroxypropyl-beta-cyclodextrin) to address abnormal cholesterol accumulation; its Phase III trial reported mixed efficacy findings in September 2026. Azafaros: Advances nizubaglustat, an investigational oral therapy targeting glycosphingolipid metabolism, with an NPC Phase III clinical study enrolling patients during 2026 Analyst Commentary: How Will Earlier Diagnosis and Reimbursement Expand Targeted Treatment Access? The Niemann-Pick Disease Type C Treatment Market is entering a new phase of targeted neurological care, driven by the introduction of approved therapies and advances in genetic diagnosis. The strongest opportunities lie in earlier patient identification, wider treatment eligibility, improved reimbursement access, and long-term disease management. Increasing clinical adoption of arimoclomol and levacetylleucine, alongside established substrate reduction therapy, is reshaping treatment pathways and creating opportunities to improve neurological outcomes and continuity of care. Niemann-Pick Disease Type C Treatment Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 191.87 Million Revenue Forecast in 2032 USD 745.00 Million Overall Growth Rate CAGR of 21.38% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Treatment Type, By Drug Type, By Patient Age Group, By Route of Administration, By Distribution Channel, By Geography By Treatment Type Substrate Reduction Therapy, Arimoclomol-Based Therapy, Levacetylleucine Therapy, Supportive Treatment By Drug Type Miglustat, Arimoclomol, Levacetylleucine By Patient Age Group Pediatric Patients, Adult Patients By Route of Administration Oral Administration, Enteral Administration By Distribution Channel Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Adoption of approved arimoclomol and levacetylleucine therapies, improved genetic diagnosis and patient identification, long-term neurological treatment requirements, expansion of specialty pharmacy distribution, improved reimbursement and rare-disease treatment access Customization Option Available upon request Frequently Asked Question About This Report Q1. How does earlier diagnosis create opportunities in the market? A1. Identifying undiagnosed patients can expand the population considered for treatment. The report cites an estimated 900 affected people in the United States, with only 300–350 diagnosed. Commercial growth depends on connecting newly identified patients with specialist assessment and funded treatment. Q2. What developments are changing the industry’s treatment landscape? A2. The introduction of MIPLYFFA and AQNEURSA has expanded options for managing neurological symptoms. Their different eligibility requirements influence the patients each medicine can serve. Manufacturers must translate treatment availability into specialist prescribing and sustained patient access. Q3. Why are specialty pharmacies important to market growth? A3. Specialty pharmacies hold an estimated 67% distribution share in 2025. They coordinate insurance approvals and medicine delivery while supporting ongoing treatment. These services are particularly important when a small patient population needs specialized medicines and consistent access over time. Q4. What factors could limit market expansion across regions? A4. Delayed diagnosis and limited reimbursement can restrict the number of patients starting therapy. Some regions also rely on imported specialty medicines and face complex approval pathways. Expanding specialist services will need to be matched by dependable supply and affordable treatment access. Q5. How is competition evolving in the industry? A5. Zevra and IntraBio participate through approved oral therapies, while other developers are investigating additional treatment approaches. Competition increasingly depends on clinical outcomes and access to eligible patients. Pipeline programs could broaden treatment choices, although their commercial prospects remain dependent on clinical and regulatory results. Sources: U.S. National Library of Medicine – Estimates That Niemann-Pick Disease Types C1 and C2 Together Affect Approximately 1 in 150,000 Individuals, With Type C1 Accounting for 95% of Cases MedlinePlus Genetics – Niemann-Pick Disease: Frequency and Genetic Subtypes U.S. FDA – Approved MIPLYFFA on September 20, 2024, Alongside Miglustat for NPC Neurological Symptoms in Patients Aged Two Years and Older; Its Pivotal Trial Enrolled 50 Patients, Including 39 Receiving Background Miglustat FDA – First Approved Treatment for Niemann-Pick Disease Type C: Eligibility and Clinical Evidence U.S. FDA – Approved AQNEURSA on September 24, 2024, for NPC Neurological Symptoms in Adults and Children Weighing at Least 15 kg, Supported by a 60-Patient, 24-Week Crossover Study FDA – AQNEURSA Approval, Patient Eligibility, and Clinical Trial Population European Medicines Agency – Lists Zavesca (Miglustat) for Progressive Neurological Manifestations of NPC in Adults and Children, With Advanz Pharma Limited as the Marketing Authorisation Holder EMA – Zavesca: Approved NPC Indication and Marketing Authorisation Information Zevra Therapeutics – Estimates Approximately 2,000 People Living With NPC Across the United States and Europe, Including 900 in the United States and 1,100 in Europe, With Only 300–350 U.S. Patients Diagnosed Zevra Therapeutics – August 2026 SEC Filing: NPC Population and Diagnosis Estimates Zevra Therapeutics – Reported USD 87.4 Million in MIPLYFFA Net Revenue During 2025, Compared With USD 10.1 Million in 2024 Zevra Therapeutics – Full-Year 2025 Financial Results and MIPLYFFA Commercial Performance Zevra Therapeutics – Reported USD 30.2 Million in MIPLYFFA Net Revenue During Q2 2026, With 184 Cumulative Prescription Enrollment Forms Since Launch and Market Access Reaching 69% of Covered Lives Zevra Therapeutics – Second-Quarter 2026 Revenue, Prescription Enrollments, and Reimbursement Access Zevra Therapeutics – Reported 132 Patients Enrolled in Its Global Arimoclomol Expanded Access Program as of June 30, 2026, Compared With 113 at December 31, 2025 Zevra Therapeutics – Global Expanded Access Program Enrollment Update Zevra Therapeutics – Discloses That Nearly Half of Patients Treated With MIPLYFFA Are Adults and That a Single Specialty Pharmacy Serves as Its Sole Distributor for MIPLYFFA and OLPRUVA Zevra Therapeutics – SEC Filing: Treated Patient Mix and Specialty Pharmacy Distribution Shionogi – Announced an Agreement on October 5, 2026, to Acquire IntraBio for USD 2.0 Billion Upfront, Adding AQNEURSA to Its Rare Disease Portfolio Subject to Closing Conditions Shionogi – Planned Acquisition of IntraBio and Expansion Into NPC Treatment Rafael Holdings – Reported Phase III TransportNPC Results on September 30, 2026, From 94 Patients; Trappsol Cyclo Missed Statistical Significance on the Primary Endpoint, While a Prespecified Background-Therapy Subgroup Showed a Significant Result Rafael Holdings – Phase III TransportNPC Results and Planned Regulatory Submission European Medicines Agency – Reports That AQNEURSA Received EU-Wide Marketing Authorisation on January 19, 2026, for Eligible NPC Patients Aged Six Years and Older and Weighing at Least 20 kg EMA – AQNEURSA: European Approval and Treatment Eligibility European Medicines Agency – Issued a Negative CHMP Opinion for Meplyffa (Arimoclomol) in July 2026 and Reported a Requested Re-Examination at Its September 2026 Meeting EMA – September 2026 CHMP Meeting: Meplyffa Re-Examination Following Negative Opinion Azafaros – Reports That Investigational Oral Nizubaglustat Entered Phase III Development in Q3 2025, Including a Pivotal Program for Niemann-Pick Disease Type C Azafaros – Nizubaglustat Late-Stage Development Program and NPC Pipeline Position Table of Contents - Global Niemann-Pick Disease Type C Treatment Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Treatment Type, Drug Type, Patient Age Group, Route of Administration, Distribution Channel, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Treatment Type, Drug Type, Patient Age Group, Route of Administration, Distribution Channel, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Treatment Type, Drug Type, Patient Age Group, Route of Administration, and Distribution Channel Investment Opportunities in the Niemann-Pick Disease Type C Treatment Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Arimoclomol-Based Therapy, Levacetylleucine Therapy, Substrate Reduction Therapy, Pediatric Treatment, Specialty Pharmacy Distribution, and Rare Disease Diagnosis Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Targeted Therapies in Niemann-Pick Disease Type C Neurological Management and Long-Term Patient Care Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory Approval, Reimbursement, and Rare Disease Treatment Access Role of Arimoclomol, Levacetylleucine, Miglustat, and Supportive Treatment in Neurological Disease Management Early Diagnosis, Genetic Screening, Specialty Pharmacy Distribution, and Long-Term Treatment Adherence Trends Global Niemann-Pick Disease Type C Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type: Substrate Reduction Therapy Arimoclomol-Based Therapy Levacetylleucine Therapy Supportive Treatment Market Analysis by Drug Type: Miglustat Arimoclomol Levacetylleucine Market Analysis by Patient Age Group: Pediatric Patients Adult Patients Market Analysis by Route of Administration: Oral Administration Enteral Administration Market Analysis by Distribution Channel: Hospital Pharmacies Specialty Pharmacies Retail Pharmacies Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Niemann-Pick Disease Type C Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Type, Patient Age Group, Route of Administration, and Distribution Channel Country-Level Breakdown: United States Canada Mexico Europe Niemann-Pick Disease Type C Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Type, Patient Age Group, Route of Administration, and Distribution Channel Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Niemann-Pick Disease Type C Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Type, Patient Age Group, Route of Administration, and Distribution Channel Country-Level Breakdown: China Japan South Korea India Australia Rest of Asia-Pacific Latin America Niemann-Pick Disease Type C Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Type, Patient Age Group, Route of Administration, and Distribution Channel Country-Level Breakdown: Brazil Mexico Argentina Rest of Latin America Middle East & Africa Niemann-Pick Disease Type C Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug Type, Patient Age Group, Route of Administration, and Distribution Channel Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Zevra Therapeutics, Inc. IntraBio, Inc. Johnson & Johnson Advanz Pharma Cyclo Therapeutics Rafael Holdings, Inc. Azafaros B.V. Shionogi & Co., Ltd. Orphazyme A/S Sanofi Takeda Pharmaceutical Company Limited Competitive Landscape and Strategic Insights Benchmarking Based on Approved Therapy Portfolios, Clinical Development, Regulatory Status, Specialty Pharmacy Access, Reimbursement Support, and Regional Presence Supplier Qualification and Rare Disease Treatment Access Analysis Arimoclomol-Based Therapy and Levacetylleucine Positioning Substrate Reduction Therapy and Supportive Care Competitiveness Genetic Diagnosis, Specialist Referral, and Long-Term Treatment Access Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Treatment Type, Drug Type, Patient Age Group, Route of Administration, Distribution Channel, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Regulatory Approval, Reimbursement, and Rare Disease Treatment Access Analysis Therapy Adoption Trends Across Substrate Reduction Therapy, Arimoclomol-Based Therapy, Levacetylleucine Therapy, and Supportive Treatment List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Treatment Type, Drug Type, Patient Age Group, Route of Administration, and Distribution Channel (2025 vs. 2032) Global Niemann-Pick Disease Type C Treatment Ecosystem and Value Chain Analysis